www.stirlingproducts.net
Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties. Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.
The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.
Stirling operates through three main business units each managed by proven industry specialist managers:
- Pharmaceutical & Healthcare
- Research & Development
- Animal Products
Stirling Products provides update on Canadian pharmaceutical plant
Stirling Products (ASX:STI) has provided an update on its Canadian pharmaceutical plant, it owns in Cape Breton, through which it will provide contract manufacturing services as well manufacture its own products.
The company has advised that its pharmaceutical plant re-validation of all plant, equipment and processes is ahead of schedule and application for inspection will be forwarded to Health Canada this week.
Following receipt of application, Health Canada then has 90 days within which to arrange an inspection following which the plant licensing is expected to issue and production can then commence.
The Company is hopeful that this inspection will be at the earlier end of the 90 period and will keep the market advised as soon as inspection is arranged.
The current fit-out and configuration of the plant provides for an annual capacity to manufacture and package over 550 million tablets, 5 million bottles and blend up to 1.5 million kg of product.


















